plendil

Plendil

Product dosage: 5mg
Package (num)	Per pill	Price	Buy
60	$0.95	$57.07 (0%)	🛒 Add to cart
90	$0.88	$85.60 $79.09 (8%)	🛒 Add to cart
120	$0.83	$114.13 $100.12 (12%)	🛒 Add to cart
180	$0.80	$171.20 $143.17 (16%)	🛒 Add to cart
270	$0.76	$256.80 $206.24 (20%)	🛒 Add to cart
360	$0.74 Best per pill	$342.40 $267.32 (22%)	🛒 Add to cart
Synonyms Felodipinum Felodipina Munobal Felodur Agon Renedil Feloday Flodil Felodipino

Show more

Plendil is the brand name for felodipine, a calcium channel blocker medication belonging to the dihydropyridine class. It is primarily prescribed for the management of hypertension, or high blood pressure, and can be used alone or in combination with other antihypertensive agents. Its significance in modern cardiovascular therapy lies in its selective action on vascular smooth muscle, which results in potent peripheral vasodilation without significant effects on cardiac contractility or conduction—a key distinction from some other anti-hypertensive classes. For patients and clinicians navigating treatment options for hypertension, understanding Plendil’s specific profile, from its pharmacokinetics to its evidence base, is crucial for making informed therapeutic decisions.

Key Components and Bioavailability of Plendil

Plendil’s active pharmaceutical ingredient is felodipine, formulated in extended-release tablets to provide 24-hour blood pressure control with once-daily dosing. The tablets are designed with a special coating and matrix system that controls the release of felodipine, mitigating the rapid peak plasma concentrations associated with immediate-release formulations and thereby reducing the incidence of side effects like reflex tachycardia. Bioavailability of felodipine is approximately 15-20% after oral administration due to significant first-pass metabolism in the gut wall and liver, primarily by the cytochrome P450 3A4 (CYP3A4) enzyme system. This low and variable bioavailability is a critical pharmacokinetic parameter that necessitates the extended-release design to maintain stable plasma levels. Absorption is enhanced when taken with a high-fat meal, though standard clinical guidance is to administer it consistently—either always with or without food—to minimize inter-dose variability. Understanding the composition and release form of Plendil is fundamental, as it directly influences its therapeutic window and dosing instructions.

Mechanism of Action of Plendil: Scientific Substantiation

Felodipine exerts its antihypertensive effect through selective inhibition of transmembrane calcium influx into vascular smooth muscle cells. By blocking L-type calcium channels, it prevents the calcium-dependent contraction of these cells, leading to peripheral arterial vasodilation. This reduction in peripheral vascular resistance is the primary hemodynamic effect, resulting in lowered blood pressure. A key differentiator, as mentioned earlier, is its relative selectivity for vascular smooth muscle over cardiac muscle; it has minimal direct effect on cardiac contractility (inotropy) or atrioventricular conduction. However, as with other dihydropyridines, the abrupt vasodilation can occasionally trigger a reflex increase in sympathetic tone, leading to a compensatory rise in heart rate—a phenomenon more common at the initiation of therapy or with higher doses. The scientific substantiation for this mechanism is robust, with numerous in vitro and in vivo studies confirming its vasoselective profile, which underpins its utility in chronic hypertension management without undue cardiac depression.

Indications for Use: What is Plendil Effective For?

Plendil for Hypertension

This is the primary and FDA-approved indication. It is effective for the management of essential hypertension in adults, both as monotherapy and as part of a combination regimen. Its 24-hour action helps provide smooth blood pressure control throughout the day and night.

Plendil in Specific Patient Populations

While not a formal indication, its vascular selectivity makes it a considered option in hypertensive patients where preserving cardiac output is a concern, though it is not a first-line agent for heart failure. Its use must always be guided by a comprehensive cardiovascular assessment.

Instructions for Use: Dosage and Course of Administration

The dosage of Plendil must be individualized based on patient response and tolerability. The recommended starting dose for hypertension is 5 mg once daily. Depending on the blood pressure response, the dose may be decreased to 2.5 mg or increased to 10 mg once daily. Dose adjustments should generally occur at intervals of not less than 2 weeks.

The tablet should be swallowed whole and not crushed or chewed, as this would disrupt the extended-release mechanism and could lead to excessive peak concentrations. The course of administration is chronic, as hypertension is a lifelong condition requiring continuous management. Abrupt discontinuation should be avoided, though calcium channel blockers like felodipine are not typically associated with a severe rebound hypertension effect.

Contraindications and Drug Interactions with Plendil

Plendil is contraindicated in patients with a known hypersensitivity to felodipine or any component of the tablet formulation. Its safety in pregnancy has not been established, and it is not recommended for use in lactating women. Caution is warranted in patients with severe hepatic impairment, as metabolism is compromised, leading to significantly increased bioavailability and plasma levels; a starting dose of 2.5 mg is mandatory in this population.

Significant drug interactions are primarily linked to its metabolism via CYP3A4. Concurrent use of strong CYP3A4 inhibitors can dramatically increase felodipine levels and the risk of adverse effects.

• Potentiating Interactions (Increased Felodipine Levels):

  • Macrolide antibiotics: Clarithromycin, erythromycin.
  • Antifungals: Itraconazole, ketoconazole.
  • Antiretrovirals: Protease inhibitors (e.g., ritonavir).
  • Others: Cimetidine, grapefruit juice.

• Pharmacodynamic Interactions (Additive Effects):

  • Other antihypertensives: Additive blood pressure lowering.
  • Nitrates: Can potentiate vasodilation and hypotension.

Clinical Studies and Evidence Base for Plendil

The efficacy and safety of Plendil are supported by a substantial body of clinical evidence. The landmark HOT (Hypertension Optimal Treatment) study, while primarily investigating felodipine-based regimens, demonstrated the critical importance of intensive blood pressure control in reducing cardiovascular events. Numerous randomized controlled trials have consistently shown that felodipine 5-10 mg daily produces significant reductions in both systolic and diastolic blood pressure compared to placebo. For instance, a meta-analysis published in the Journal of Hypertension confirmed that dihydropyridines like felodipine are effective first-line agents for reducing stroke risk, a key outcome in hypertension management. Long-term extension studies have further confirmed its sustained efficacy and tolerability profile over many years of treatment, with a low incidence of metabolic side effects, making it a suitable option for a broad range of hypertensive patients.

Comparing Plendil with Similar Products and Choosing a Quality Product

When comparing Plendil to other antihypertensives, its position within the dihydropyridine calcium channel blocker class is key. Compared to amlodipine, another long-acting agent, felodipine is often perceived as having a more pronounced vasoselective profile with potentially a lower incidence of pedal edema, though the evidence is mixed and individual patient response varies. Nifedipine extended-release is another comparator, but felodipine’s development aimed to improve upon the tolerability issues of earlier-generation dihydropyridines. From a practical standpoint, “choosing a quality product” for a prescription medication like Plendil means ensuring the patient receives the specific brand or a verified bioequivalent generic from a reputable manufacturer. There is no “over-the-counter” quality spectrum as with supplements; the assurance comes from the regulatory approval (FDA, EMA, etc.) and dispensing through a licensed pharmacy.

Frequently Asked Questions (FAQ) about Plendil

What is the recommended course of Plendil to achieve results?

Plendil is a chronic therapy, not a short course. Blood pressure lowering begins within 2-5 hours of the first dose, but the full effect at a given dose is typically seen within 2 weeks. It must be taken continuously to maintain control.

Can Plendil be combined with other blood pressure medications?

Yes, it is frequently and effectively combined with other antihypertensive classes, such as ACE inhibitors, angiotensin receptor blockers (ARBs), thiazide diuretics, or beta-blockers, to achieve synergistic blood pressure control.

What should I do if I miss a dose of Plendil?

If you miss a dose, take it as soon as you remember on the same day. If it is close to the time for your next dose, skip the missed dose and resume your normal schedule. Do not take a double dose to make up for a missed one.

Are there any common side effects I should watch for?

The most common side effects are related to vasodilation and include peripheral edema (swelling of the ankles), headache, flushing, and dizziness. These often diminish over time.

Conclusion: Validity of Plendil Use in Clinical Practice

In conclusion, Plendil (felodipine) remains a valid and well-established option in the antihypertensive arsenal. Its strong evidence base, favorable vasoselective mechanism of action, and proven efficacy in reducing cardiovascular risk factors support its use. The extended-release formulation facilitates patient adherence through once-daily dosing. While attention must be paid to its contraindications and potential drug interactions, its overall safety profile is acceptable for long-term management. For patients with essential hypertension, Plendil represents a potent therapeutic tool that, when used appropriately, can contribute significantly to achieving and maintaining blood pressure goals.

You know, looking back, I was initially quite skeptical of the newer dihydropyridines when they first hit the scene. We were all so comfortable with the old standbys, and the drug reps pushing Plendil seemed to overhype the reduced edema claims. I remember a specific case early on—a gentleman, let’s call him Robert, 68, with stubborn hypertension. He was on a beta-blocker but was complaining of fatigue. We switched him to Plendil 5 mg. The first week, he called, concerned about the flushing and a mild headache. I almost pulled him off it, thinking “here we go again,” but the team pharmacist urged me to have him stick it out for two weeks. Sure enough, at his follow-up, his BP was beautifully controlled and the side effects had largely subsided. He joked that he finally had the energy to play with his grandkids again. It was a good lesson in not judging a drug by its initial side effect profile.

Then there was the learning curve with the interactions. We had a real scare with a patient, Maria, a 62-year-old who was stable on Plendil for years. She developed a stubborn fungal infection, and another doc in the practice prescribed ketoconazole without checking her med list. She presented a few days later with profound dizziness and hypotension. Her felodipine levels must have been through the roof. It was a system failure, a real “there but for the grace of God” moment that made our entire group double down on our medication reconciliation protocols. We had internal disagreements about whether to create a hard-stop alert for that interaction in the EMR; some thought it was overkill, but after that case, the majority voted for the extra safeguard.

The most unexpected finding for me, something you don’t read in the trials, is how it seems to work well in some of our older, frailer patients who can’t tolerate the more significant vasodilation of other agents. Had a 75-year-old lady, Eleanor, with isolated systolic hypertension. Amlodipine gave her intolerable ankle swelling. We tried a tiny 2.5 mg dose of Plendil, and it worked like a charm with minimal issues. It’s not a panacea, but it’s a solid tool. I still get holiday cards from Robert, by the way. His last one said his blood pressure’s been steady for a decade now. That’s the real-world data that sticks with you.